often justifiable. Above all, we should remember that coronary atheroma is an active process that demands active treatment. We tend to overlook this fact because there is no simple, cheap, and painless method of visualising coronary arterial lesions. But just because we cannot see them we must not ignore them.
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Hepatitis in pregnancy
A recent paper from Kashmir1 has renewed interest in viral hepatitis in pregnancy. This was a prospective study carried out during a water-borne epidemic of proved non-A, non-B hepatitis which showed that its incidence in pregnancy, 17",, was eight times that in non-pregnant women. Hepatitis was more common in the second and third trimesters of pregnancy, developing in 19%" of women compared with only 9°0 in the first trimester. Fulminant hepatic failure was also more common in pregnancy-22°% compared with 3",, of men and none of the non-pregnant women with hepatitis. In all, nine patients presented with fulminant hepatic failure in the last trimester and seven died, five with the fetus undelivered. Non-fulminant hepatitis in pregnancy did not, however, cause any increase in maternal or fetal loss. Both the incidence and severity of hepatitis in pregnancy vary widely around the world. In Western Europe and North America Sever and White2 found a low incidence of clinical hepatitis, one in 20 000. In another collective series3 a figure of one in 3000 was recorded for North America and Northern Europe, whereas in the Middle East, Africa, and India the reported incidence is around 30/. Findings similar to those from Kashmir have been reported from Iran by Borhanmanesh,4 who in a combined prospective and retrospective study of 61 pregnant women found that hepatitis developed much more frequently in the last trimester and that fulminant hepatic failure was also more frequent. Nevertheless, the lack of a standard definition of fulminant hepatic failure means that results from different trials must be interpreted with caution.
The reported effects of hepatitis on the course and outcome of pregnancy show a similar worldwide variation, and there are important differences between the Iranian and Indian studies. In Iran premature delivery or fetal death occurred in half of the cases of non-fulminant hepatitis, and in only one case of the 29 with fulminant hepatic failure did pregnancy continue. In contrast, non-fulminant hepatitis in Kashmir did not have any important influence on the course of pregnancy, and fetal loss in fatal fulminant hepatic failure was as a direct result of the mother's death. In a prospective study in North America Siegel et ala failed to show an increase in congenital abnormality or fetal mortality after non-fulminant hepatitis. Similar findings have been reported by Hieber et al,6 whose retrospective analysis found no increase in congenital malformation, stillbirth, abortion, or intrauterine malnutrition, though the incidence of prematurity was increased (270'). Earlier reports of an increase in Down's syndrome after hepatitis in pregnancy7 have not been substantiated in several carefully controlled epidemiological studies.8
There is no evidence of transmission of hepatitis to the infant for hepatitis A or for non-A, non-B hepatitis. Vertical transmission does occur with hepatitis B, but the frequency varies with racial background. In Taiwan When hepatitis develops in a pregnant woman (whether it is type A, type B, or non-A, non-B, as in the Indian outbreak) the pregnancy should be allowed to continue to term, provided that placental function is not impaired and hepatic function is stable. Signs of fetal distress, poor progress, or rapid deterioration in maternal condition are all indications for rapid delivery by caesarean section if necessary. If the hepatitis becomes fulminant prompt delivery by caesarean section is recommended to improve the chances of the mother's recovering. Deterioration in the maternal condition may, however, continue after delivery in some cases of fulminant hepatic failure caused by acute fatty liver of pregnancy. Epidural anaesthesia is preferable, and should be preceded when necessary by transfusion of fresh-frozen plasma and fresh platelet concentrate to avoid excessive bleeding during delivery. In other respects the management of fulminant hepatic failure is the same as in nonpregnant women. Only 0-5% of 475 patients with abdominal symptoms seen in 1975 were found to have antibodies to Y enterocolitica compared with 2-7% of sera from 1233 patients examined in 1980 at the yersinia reference laboratory in Leicester (N S Mair, "Yersinia infection in the UK and Eire with special reference to yersinia enterocolitica," paper given at the WHO meeting in Paris in April 1981) . The clinical manifestations of yersinia infection include acute enteritis, fever, and diarrhoea in children, and an acute terminal ileitis or mesenteric adenitis in adults. Some patients have associated erythema nodosum and polyarthritis.'0 Many of the patients have operations for appendicitis suspected on clinical grounds; typically the surgeon finds an inflamed terminal ileum, with local lymphadenopathy. The appendix and caecum may also be affected. 
